A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Pfizer

Status

Active, not recruiting

Conditions

Prostate Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT06733337

C3441050

Details and patient eligibility

About

The purpose of this study is to learn about the safety of TALZENNA in patients with BRCA mutation-positive metastatic castration-resistant prostate cancer. BRCA mutation positive means any changes to the BRCA gene. Metastasis means the cancer that has spread to other parts of the body. Castration-resistant prostate cancer means the prostate cancer that keeps growing even when the amount of male sex hormone in the body is reduced to very low levels. Prostate is a male sex organ.

The study is seeking for participants:

with BRCA mutation-positive metastatic castration-resistant prostate cancer
who have not used this study medicine before. All patients in this study will receive TALZENNA according to the prescriptions.

Patients will be followed up to 52 weeks (12 months) from the day of start of treatment start (Day 1). However, in cases where treatment has been completed or stopped less than 52 weeks (12 months) after the start of giving study medicine, the participants will be checked until completion (discontinuation) of treatment.

Enrollment

1 patient

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion criteria